Open | - |
Close | - |
Volume / Avg. | 2.922K / 153.333K |
Day Range | - - - |
52 Wk Range | 4.004 - 40.600 |
Market Cap | $101.110M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 49 |
Short Interest | 142.56% |
Days to Cover | 7.58 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Outlook Therapeutics (NASDAQ: OTLK) through any online brokerage.
Other companies in Outlook Therapeutics’s space includes: Vincerx Pharma (NASDAQ:VINC), Anixa Biosciences (NASDAQ:ANIX), Vaxxinity (NASDAQ:VAXX), CARISMA Therapeutics (NASDAQ:CARM) and Barinthus Biotherapeutics (NASDAQ:BRNS).
The latest price target for Outlook Therapeutics (NASDAQ: OTLK) was reported by Chardan Capital on Thursday, February 15, 2024. The analyst firm set a price target for 3.00 expecting OTLK to fall to within 12 months (a possible -61.39% downside). 18 analyst firms have reported ratings in the last year.
The stock price for Outlook Therapeutics (NASDAQ: OTLK) is $7.77 last updated Today at March 19, 2024 at 8:54 AM EDT.
There are no upcoming dividends for Outlook Therapeutics.
Outlook Therapeutics’s Q2 earnings are confirmed for Monday, May 13, 2024.
There is no upcoming split for Outlook Therapeutics.
Outlook Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.